Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Subscribe To Our Newsletter & Stay Updated
